Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Summary: The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations. The coexistence of the T790M resistance mutation with another EGFR mutation in treatment-naive patient...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
April 2017
|
| In: |
The lancet. Respiratory medicine
Year: 2017, Jahrgang: 5, Heft: 5, Pages: 435-444 |
| ISSN: | 2213-2619 |
| DOI: | 10.1016/S2213-2600(17)30129-7 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/S2213-2600(17)30129-7 Verlag, Volltext: http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(17)30129-7/abstract 
|
| Verfasserangaben: | Prof Rafael Rosell, MD, Prof Urania Dafni, ScD, Enriqueta Felip, MD, Alessandra Curioni-Fontecedro, MD, Oliver Gautschi, MD, Solange Peters, MD, Bartomeu Massutí, MD, Ramon Palmero, MD, Santiago Ponce Aix, MD, Enric Carcereny, MD, Martin Früh, MD, Miklos Pless, MD, Sanjay Popat, FRCP, Athanasios Kotsakis, MD, Sinead Cuffe, MD, Paolo Bidoli, MD, Adolfo Favaretto, MD, Patrizia Froesch, MD, Noemí Reguart, MD, Javier Puente, MD, Linda Coate, MD, Prof Fabrice Barlesi, MD, Daniel Rauch, MD, Prof Michael Thomas, MD, Carlos Camps, MD, Jose Gómez-Codina, MD, Margarita Majem, MD, Rut Porta, MD, Riyaz Shah, FRCP, Emer Hanrahan, MRCPI, Roswitha Kammler, BA, Barbara Ruepp, PharmD, Manuela Rabaglio, MD, Marie Kassapian, MSc, Niki Karachaliou, MD, Rachel Tam, BSc, David S Shames, PhD, Miguel A Molina-Vila, PhD, Dr Rolf A Stahel for the BELIEF collaborative group |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1572115203 | ||
| 003 | DE-627 | ||
| 005 | 20230426124246.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180418s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S2213-2600(17)30129-7 |2 doi | |
| 035 | |a (DE-627)1572115203 | ||
| 035 | |a (DE-576)502115203 | ||
| 035 | |a (DE-599)BSZ502115203 | ||
| 035 | |a (OCoLC)1341006808 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Rosell, Rafael |e VerfasserIn |0 (DE-588)1155863569 |0 (DE-627)1018345426 |0 (DE-576)501913149 |4 aut | |
| 245 | 1 | 0 | |a Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF) |b an international, multicentre, single-arm, phase 2 trial |c Prof Rafael Rosell, MD, Prof Urania Dafni, ScD, Enriqueta Felip, MD, Alessandra Curioni-Fontecedro, MD, Oliver Gautschi, MD, Solange Peters, MD, Bartomeu Massutí, MD, Ramon Palmero, MD, Santiago Ponce Aix, MD, Enric Carcereny, MD, Martin Früh, MD, Miklos Pless, MD, Sanjay Popat, FRCP, Athanasios Kotsakis, MD, Sinead Cuffe, MD, Paolo Bidoli, MD, Adolfo Favaretto, MD, Patrizia Froesch, MD, Noemí Reguart, MD, Javier Puente, MD, Linda Coate, MD, Prof Fabrice Barlesi, MD, Daniel Rauch, MD, Prof Michael Thomas, MD, Carlos Camps, MD, Jose Gómez-Codina, MD, Margarita Majem, MD, Rut Porta, MD, Riyaz Shah, FRCP, Emer Hanrahan, MRCPI, Roswitha Kammler, BA, Barbara Ruepp, PharmD, Manuela Rabaglio, MD, Marie Kassapian, MSc, Niki Karachaliou, MD, Rachel Tam, BSc, David S Shames, PhD, Miguel A Molina-Vila, PhD, Dr Rolf A Stahel for the BELIEF collaborative group |
| 264 | 1 | |c April 2017 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 18.04.2018 | ||
| 520 | |a Summary: The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations. The coexistence of the T790M resistance mutation with another EGFR mutation in treatment-naive patients has been associated with a shorter progression-free survival to EGFR inhibition than in the absence of the T790M mutation. To test this hypothesis clinically, we developed a proof-of-concept study, in which patients with EGFR-mutant NSCLC were treated with the combination of erlotinib and bevacizumab, stratified by the presence of the pretreatment T790M mutation. | ||
| 700 | 1 | |a Thomas, Michael |e VerfasserIn |0 (DE-588)1054438781 |0 (DE-627)79152213X |0 (DE-576)41027089X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The lancet. Respiratory medicine |d Oxford : Elsevier, 2013 |g 5(2017), 5, Seite 435-444 |w (DE-627)737292180 |w (DE-600)2704917-6 |w (DE-576)379472759 |x 2213-2619 |7 nnas |a Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF) an international, multicentre, single-arm, phase 2 trial |
| 773 | 1 | 8 | |g volume:5 |g year:2017 |g number:5 |g pages:435-444 |g extent:10 |a Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF) an international, multicentre, single-arm, phase 2 trial |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S2213-2600(17)30129-7 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(17)30129-7/abstract |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180418 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1054438781 |a Thomas, Michael |m 1054438781:Thomas, Michael |d 910000 |d 950000 |d 950900 |e 910000PT1054438781 |e 950000PT1054438781 |e 950900PT1054438781 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 24 | ||
| 999 | |a KXP-PPN1572115203 |e 300635012X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"note":["Gesehen am 01.04.14"],"recId":"737292180","type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"The lancet <London> / Respiratory medicine"}],"language":["eng"],"pubHistory":["1.2013 -"],"title":[{"partname":"Respiratory medicine","title":"The lancet","title_sort":"lancet"}],"disp":"Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF) an international, multicentre, single-arm, phase 2 trialThe lancet. Respiratory medicine","part":{"text":"5(2017), 5, Seite 435-444","year":"2017","pages":"435-444","issue":"5","volume":"5","extent":"10"},"id":{"zdb":["2704917-6"],"issn":["2213-2619"],"eki":["737292180"]},"origin":[{"dateIssuedKey":"2013","publisherPlace":"Oxford","publisher":"Elsevier","dateIssuedDisp":"2013-"}]}],"physDesc":[{"extent":"10 S."}],"recId":"1572115203","note":["Gesehen am 18.04.2018"],"language":["eng"],"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"April 2017"}],"person":[{"family":"Rosell","display":"Rosell, Rafael","role":"aut","given":"Rafael"},{"given":"Michael","family":"Thomas","display":"Thomas, Michael","role":"aut"}],"id":{"doi":["10.1016/S2213-2600(17)30129-7"],"eki":["1572115203"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Prof Rafael Rosell, MD, Prof Urania Dafni, ScD, Enriqueta Felip, MD, Alessandra Curioni-Fontecedro, MD, Oliver Gautschi, MD, Solange Peters, MD, Bartomeu Massutí, MD, Ramon Palmero, MD, Santiago Ponce Aix, MD, Enric Carcereny, MD, Martin Früh, MD, Miklos Pless, MD, Sanjay Popat, FRCP, Athanasios Kotsakis, MD, Sinead Cuffe, MD, Paolo Bidoli, MD, Adolfo Favaretto, MD, Patrizia Froesch, MD, Noemí Reguart, MD, Javier Puente, MD, Linda Coate, MD, Prof Fabrice Barlesi, MD, Daniel Rauch, MD, Prof Michael Thomas, MD, Carlos Camps, MD, Jose Gómez-Codina, MD, Margarita Majem, MD, Rut Porta, MD, Riyaz Shah, FRCP, Emer Hanrahan, MRCPI, Roswitha Kammler, BA, Barbara Ruepp, PharmD, Manuela Rabaglio, MD, Marie Kassapian, MSc, Niki Karachaliou, MD, Rachel Tam, BSc, David S Shames, PhD, Miguel A Molina-Vila, PhD, Dr Rolf A Stahel for the BELIEF collaborative group"]},"title":[{"subtitle":"an international, multicentre, single-arm, phase 2 trial","title":"Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF)","title_sort":"Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF)"}]} | ||
| SRT | |a ROSELLRAFAERLOTINIBA2017 | ||